Selvigaltin (GB1211), an orally out there small molecule galectin-3 inhibitor designed as being a cure for liver fibrosis and cirrhosis, was evaluated to evaluate the effect of hepatic impairment on its pharmacokinetics and basic safety to deal with regulatory specifications. Table 4 Statistical evaluation of dose proportionality from the pharmacokinetic https://selvigaltin-galectin-3-in43219.luwebs.com/40015615/detailed-notes-on-1978336-95-6